http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Cheoul Cho (검색결과 335 건)
- 무료
- 기관 내 무료
- 유료
-
Cho, Eun Young,Choi, Chang Soo,Kim, Tae Hyeoun,Sohn, Young Woo,Cho, Ji-Hyun,Moon, Heung-Bae,Shin, Sae Ron,Kim, Haak Cheoul 圓光大學校 醫科學硏究所 2008 圓光醫科學 Vol.23 No.1
Background and Aims: Although hepatitis Be Antigen(HBeAg) seroconversion to anti-HBe is often associated with remission of liver disease, a considerable portion of HBeAg negative chronic hepatitis B virus(HBV) infected patients still suffer from active liver disease. Precore and core promoter mutation of HBV have been reported in the worldwide but their clinical significance have not been determined. We aimed to study the inter-relationships of clinical parameters such as serum HBV-DNA, serum aminotransferase, intrahepatic expression of hepatitis B core Antigen(HBcAg) and histological activity in the HBeAg negative young chronic HBV carriers and to study the differences of clinical parameter according to precore mutation. Methods: The study group included 35 young male patients with biopsy-proven chronic hepatitis B(All HBeAg-negative groups). Results:1. HBV-DNA were positively correlated to serum transaminase, lobular activity, portal activity, fibrosis and grade of intrahepatic HBcAg expression(p<0.05), but not correlated to periportal activity. 2. Serum AST and ALT were positively correlated with serum HBV-DNA, lobular activity, and grade of cytoplasmic HBcAg expression(p<0.001). 3. Nt. 1896 mutation(A, A/G) were not correlated with serum HBV-DNA, transaminase, grade and site of intrahepatic HBcAg expression, and histologic activity. Precore mutation of HBeAg negative group had a positive correlation with the number of apparent amino acid substitution(p=0.017). Conlusion: Activity of hepatitis in HBeAg negative young chronic B viral hepatitis was not affected by precore mutation. However, the level of serum HBV-DNA in HBeAg negative young chronic B viral hepatitis were strongly correlated to liver injury.
-
Breeding of Powdery Mildew Resistant Squash 'Miso'
Cho, Myeong-Cheoul,Om, Young-Hyun,Huh, Yun-Chan,Cheong, Seung-Ryong,Kim, Dae-Hyun,Mok, Il-Gin Korean Association of Organic Agriculture 2011 韓國有機農業學會誌 Vol.19 No.S
A new powdery mildew resistant squash (Cucurbita moschata Duch.) 'Miso' was bred from a cross between powdery mildew resistant true variety 'Sangol' and powdery mildew susceptible inbred line 'Seoulmadi' at National Institute of Horticultural & Herbal Science (NIHHS). The 'Miso' variety was vigorous and highly resistant to powdery mildew. It showed white green fruit color. The variety yielded 21.3MT/ha which is 52% more than control variety.
-
Recent Activities on Breeding Anthracnose Resistant Pepper at AVRDC- The World Vegetable Center
Myeong-Cheoul Cho,Patcharaporn Suwor,Shin-Wen Lin,Zong-Ming Sheu,Jaw-Fen Wang,Suchila Techawongstien,Roland Schafleitner,Paul Gniffke,Sanjeet Kumar 한국육종학회 2012 한국육종학회 심포지엄 Vol.2012 No.07
Pre- and postharvest anthracnose fruit rot is a serious disease of hot peppers (Capsicum annuum) throughout the world. AVRDC has pursued breeding for resistance to anthracnose for more than 10 years and has distributed a number of resistant lines in Asia and Africa. Recently AVRDC has identified highly aggressive isolates of Colletotrichum acutatum that have prompted renewed efforts to identify new anthracnose resistance genes. This study aimed to characterize resistance to specific pathogen strains in an array of newly identified breeding lines, and to validate one simple sequence repeat (SSR) and two sequence characterized amplified region (SCAR) markers linked to the anthracnose resistance locus. Forty-four accessions and two populations (two resistant parents and one susceptible parent, to F1, four backcross populations, and two F2 populations) are currently (Spring 2012) being screened against two pathotypes of C. acutatum collected in Taiwan. Pepper entries include C. annuum, C. baccatum, C. chinense, and their inter-specific progenies. Screening methods include field screening, spray and microinjection assays on green and red-ripe fruits, and molecular assays using SSR and SCAR markers linked to anthracnose resistance. Progress will be shared on initial screening results, evaluation of horticultural characteristics, and selection of potential lines for crossing programs.
-
( Haak Cheoul Kim ),( Eun Young Cho ),( Young Bum Cho ),( Ji Won Kim ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.-
Background and Aims: For Hepatitis C virus (HCV) infection, pegylated interferon and ribavirin treatment are used as standard treatments, but they can make various hematologic adverse events. If such an adverse event arises, does should be reduced dosage, which may drop the treatment response. Also it is often reported that anemia occurrence can be an indicator of the good treatment response. We confirmed that Mean corpuscular volume (MCV) increase was not unusual during the HCV standard treatment and tried to find out the meaning of MCV increase during the process of HCV treatment. Methods: The subjects of the study were 60 outpatients who visited Wonkwang University Hospital because of chronic C viral hepatitis and were treated with pegylated interferon and ribavirinfrom from 2005 to 2010 and whose SVR could be identified. The medical records of the subjects were analyzed. CBC, blood chemistry, HCV RNA (copies/mL), T4 free and TSH were reviewed at 0, 4, 12, 24, 48 and 72 week after the treatment, and aspartate aminotransferase to platelet ratio index(APRI) was calculated based on the blood test result. Additionally, abdomen ultrasound scan was performed to check if there is a cirrhotic change. Results: 1. The subjects were 31 males and 29 females by gender, and 19 Genotype 1, 40 Genotype 2 and 1 Genotype 3 by Genotype. 24 patients were treated with interferon α2a, and 36 with pegylated interferon α2b. Regarding ribavirin dose, 11 patients had less than 800mg, 37 patients had 800mg ∼ <1000mg, and 12 patients had ≥1000mg. Ten patients showed significant drinking history (80 g/day). 2. When classifying the group with the baseline of MCV 95fL before the treatment (Group 1, MCV< 95 fL; Group 2, MCV ≥95 fL) 16 subjects showed over 95 fL MCV, and there was no significantly different factors between groups (all≥0.05). The only significantly different factor was average age such as 59.1±13.5 in Group 1 and 64.0±7.19 in Group 2, which showed borderline significance (p=0.076). 3. Regarding the increase of MCV during the treatment, it increased regardless of Genotype at 4, 12, and 24 weeks and decreased from 48 weeks. (Genotype 1: 90.92±3.62, 90.95±4.03, 94.52±6.74, 97.43±7.31, 93.68±5.36, 91.36±5.56 in week 0, week 4, week 12 (p=0.000), week 24 (p=0.024), week 48, week 72, retrospectively; Genotype 2: 92.26±5.87, 93.54±5.66, 97.13±6.55, 98.08±7.11, 92.72±4.82, 92.58±4.99 in week 0, week 4 (p=0.000), week 12 (p=0.000), week 24 (p=0.000), week 48, week 72, retrospectively) 4. There was statistically significant difference in Hemoglobin (week 0, 2, 4, 12, 24) and platelet count (week 0, 2, 12, 24, 48, 72) and albumin (week 0, 4, 12, 24, 48, 72) (all p≤0.05) when dividing group with the standard of MCV ≥100fL (Group 3, MCV< 100 fL; Group 4, MCV ≥100 fL), which showed significant correlation when it was divided by APRI >0.08. Group 4 had more patients who showed cirrhotic changes on the sonography comparing to Group 3 (3/29(21.4%) in Group 3, 11/31(78.6%) in Group 4, p=0.021). Conclusions: Although MCV increase during the treatment was not related with the treatment response, it seemed to be related with chronicity of hepatitis. Thus, such patients should be closely observed even after the termination of the treatment.
-
-
( Haak Cheoul Kim ),( Eun Young Cho ),( Young Bum Cho ),( Ji Won Kim ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1
Background and Aims: For Hepatitis C virus (HCV) infection, pegylated interferon and ribavirin treatment are used as standard treatments, but they can make various hematologic adverse events. If such an adverse event arises, does should be reduced dosage, which may drop the treatment response. Also it is often reported that anemia occurrence can be an indicator of the good treatment response. We confirmed that Mean corpuscular volume (MCV) increase was not unusual during the HCV standard treatment and tried to find out the meaning of MCV increase during the process of HCV treatment. Methods: The subjects of the study were 60 outpatients who visited Wonkwang University Hospital because of chronic C viral hepatitis and were treated with pegylated interferon and ribavirinfrom from 2005 to 2010 and whose SVR could be identified. The medical records of the subjects were analyzed. CBC, blood chemistry, HCV RNA (copies/mL), T4 free and TSH were reviewed at 0, 4, 12, 24, 48 and 72 week after the treatment, and aspartate aminotransferase to platelet ratio index(APRI) was calculated based on the blood test result. Additionally, abdomen ultrasound scan was performed to check if there is a cirrhotic change. Results: 1. The subjects were 31 males and 29 females by gender, and 19 Genotype 1, 40 Genotype 2 and 1 Genotype 3 by Genotype. 24 patients were treated with interferon α2a, and 36 with pegylated interferon α2b. Regarding ribavirin dose, 11 patients had less than 800mg, 37 patients had 800mg ~ <1000mg, and 12 patients had ≥1000mg. Ten patients showed significant drinking history (80 g/day). 2. When classifying the group with the baseline of MCV 95fL before the treatment (Group 1, MCV< 95 fL; Group 2, MCV ≥95 fL) 16 subjects showed over 95 fL MCV, and there was no significantly different factors between groups (all≥0.05). The only significantly different factor was average age such as 59.1±13.5 in Group 1 and 64.0±7.19 in Group 2, which showed borderline significance (p=0.076). 3. Regarding the increase of MCV during the treatment, it increased regardless of Genotype at 4, 12, and 24 weeks and decreased from 48 weeks. (Genotype 1: 90.92±3.62, 90.95±4.03, 94.52±6.74, 97.43±7.31, 93.68±5.36, 91.36±5.56 in week 0, week 4, week 12 (p=0.000), week 24 (p=0.024), week 48, week 72, retrospectively; Genotype 2: 92.26±5.87, 93.54±5.66, 97.13±6.55, 98.08±7.11, 92.72±4.82, 92.58±4.99 in week 0, week 4 (p=0.000), week 12 (p=0.000), week 24 (p=0.000), week 48, week 72, retrospectively) 4. There was statistically significant difference in Hemoglobin (week 0, 2, 4, 12, 24) and platelet count (week 0, 2, 12, 24, 48, 72) and albumin (week 0, 4, 12, 24, 48, 72) (all p≤0.05) when dividing group with the standard of MCV ≥100fL (Group 3, MCV< 100 fL; Group 4, MCV ≥100 fL), which showed significant correlation when it was divided by APRI >0.08. Group 4 had more patients who showed cirrhotic changes on the sonography comparing to Group 3 (3/29(21.4%) in Group 3, 11/31(78.6%) in Group 4, p=0.021). Conclusions: Although MCV increase during the treatment was not related with the treatment response, it seemed to be related with chronicity of hepatitis. Thus, such patients should be closely observed even after the termination of the treatment.
-
-
Breeding of Powdery Mildew Resistant Squash ‘Miso’
Myeong-Cheoul Cho,Young-Hyun Om,Yun-Chan Huh,Seung-Ryong Cheong,Dae-Hyun Kim,II-Gin Mok 한국유기농업학회 2011 韓國有機農業學會誌 Vol.19 No.S
A new powdery mildew resistant squash (Cucurbita moschata Duch.) ‘Miso' was bred from a cross between powdery mildew resistant true variety ‘Sangol’ and powdery mildew susceptible inbred line ‘Seoulmadi’ at National Institute of Horticultural & Herbal Science (NIHHS). The ‘Miso’ variety was vigorous and highly resistant to powdery mildew. It showed white green fruit color. The variety yielded 21.3MT/ha which is 52% more than control variety.
-
-
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
